Who makes HM71224 Multiple ascending dose?

HM71224 Multiple ascending dose is developed by Hanmi Pharmaceutical Company Limited.

What development phase is HM71224 Multiple ascending dose in?

HM71224 Multiple ascending dose is in Phase 1.

Last reviewed 2026-04-20 · How we verify

HM71224 Multiple ascending dose

Hanmi Pharmaceutical Company Limited · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	HM71224 Multiple ascending dose
Sponsor	Hanmi Pharmaceutical Company Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HM71224 Multiple ascending dose CI brief — competitive landscape report
HM71224 Multiple ascending dose updates RSS · CI watch RSS
Hanmi Pharmaceutical Company Limited portfolio CI